The art of innovation: clinical development of trastuzumab deruxtecan and redefining how antibody-drug conjugates target HER2-positive cancers.

Ann Oncol

Oncology Research and Development, AstraZeneca, Gaithersburg, USA; Medicine and Medical Oncology, Paris-Sud University, Orsay, France.

Published: March 2020

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.annonc.2019.11.019DOI Listing

Publication Analysis

Top Keywords

art innovation
4
innovation clinical
4
clinical development
4
development trastuzumab
4
trastuzumab deruxtecan
4
deruxtecan redefining
4
redefining antibody-drug
4
antibody-drug conjugates
4
conjugates target
4
target her2-positive
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!